412 related articles for article (PubMed ID: 30663077)
1. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome.
Saito YA; Almazar AE; Tilkes KE; Choung RS; Van Norstrand MD; Schleck CD; Zinsmeister AR; Talley NJ
Aliment Pharmacol Ther; 2019 Feb; 49(4):389-397. PubMed ID: 30663077
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
Leighton MP; Lam C; Mehta S; Spiller RC
Trials; 2013 Jan; 14():10. PubMed ID: 23302220
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome.
Saito YA; Rey E; Almazar-Elder AE; Harmsen WS; Zinsmeister AR; Locke GR; Talley NJ
Am J Gastroenterol; 2010 Jan; 105(1):170-7. PubMed ID: 19809408
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
Chen M; Tang TC; Wang Y; Shui J; Xiao XH; Lan X; Yu P; Zhang C; Wang SH; Yao J; Zheng H; Huang DQ
Aliment Pharmacol Ther; 2018 Jul; 48(2):160-168. PubMed ID: 29856472
[TBL] [Abstract][Full Text] [Related]
8. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
Wouters MM; Balemans D; Van Wanrooy S; Dooley J; Cibert-Goton V; Alpizar YA; Valdez-Morales EE; Nasser Y; Van Veldhoven PP; Vanbrabant W; Van der Merwe S; Mols R; Ghesquière B; Cirillo C; Kortekaas I; Carmeliet P; Peetermans WE; Vermeire S; Rutgeerts P; Augustijns P; Hellings PW; Belmans A; Vanner S; Bulmer DC; Talavera K; Vanden Berghe P; Liston A; Boeckxstaens GE
Gastroenterology; 2016 Apr; 150(4):875-87.e9. PubMed ID: 26752109
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
Tack JF; Miner PB; Fischer L; Harris MS
Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.
Lacy BE; King J; Shortino D; Schaumburg C; Haag-Molkenteller C; Chey WD
Neurogastroenterol Motil; 2022 Dec; 34(12):e14448. PubMed ID: 35975404
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
[TBL] [Abstract][Full Text] [Related]
14. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
Kemppinen A; Howell C; Allgar V; Dodd M; Gregson J; Knowles C; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
Trials; 2020 Jan; 21(1):122. PubMed ID: 32000822
[TBL] [Abstract][Full Text] [Related]
15. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo.
Lyra A; Hillilä M; Huttunen T; Männikkö S; Taalikka M; Tennilä J; Tarpila A; Lahtinen S; Ouwehand AC; Veijola L
World J Gastroenterol; 2016 Dec; 22(48):10631-10642. PubMed ID: 28082816
[TBL] [Abstract][Full Text] [Related]
16. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A
Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028
[TBL] [Abstract][Full Text] [Related]
18. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
[TBL] [Abstract][Full Text] [Related]
20. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]